Zealand Pharma is a biotechnology company that discovers, designs, and develops peptide-based medicines. It focuses on gastrointestinal, metabolic, and other specialty diseases and offers Glepaglutide for the treatment of short bowel syndrome (SBS), Dasiglucagon for the treatment of diabetes and congenital hyperinsulinism (CHI), ZP8396, an amylin analogue for obesity treatment, etc.